Fuisz receives U.S. Patent for new generation of glucose, analyte analyzers

Fuisz Pharma (www.fuisz.com) today announced the issuance of U.S. Patent 7,824,612 ("Bodily fluid analyzer, and system including same and method for programming same").

This patent enables and protects the new generation of glucose and analyte analyzers for home and institutional use.  It is directed at enabling the caregiver to provide better patient care in this era of wireless interconnectivity.  It also provides the pharmaceutical industry with a better tool for judging the efficacy of existing drug agents as well as drug development targets. For the first time, the up and down limits for any analyte range and/or alert communication are easily preset on an individual basis by the Caregiver, physician or pharmaceutical company.

Joseph Matus Fuisz, Managing Member of Fuisz Pharma, stated, "We have jumped a generation here. No longer is there a limitation of a generic feedback for analyte limits for notification. Now, with this IP, we allow custom analyte level monitoring for the physician or the pharmaceutical company. The ability to custom set glucose, potassium or any other analyte limits means better patient care, better record keeping, better drug studies and more cost efficient analysis. This IP enables the strategic planning of a wide area of wellness, analyzer, home care and institutional companies to become a reality.  It fits the new paradigm of real-time testing, informed decision-making, and individualized care."

He added, "Under this art, the caregiver custom sets the parameters of physiological concern. No more reliance on generic analysis. The concern in the healthy 20 year old is not at the level of the frail 80 year old. We must provide the best care to both. Fuisz is proud that with this issued IP, that is now enabled."

SOURCE Fuisz Pharma